Aug 2026· Frontiers in Oncology· Vol 16· 0 citations· 117 references
Medicine
TL;DR
A central argument about treatment sequencing is advanced: because CLDN18.2 expression declines progressively under therapeutic pressure, continuous target-plus-chemotherapy acts on an eroding antigen substrate, for patients with high, homogeneous baseline expression, an early intensive induction followed by CLDN18.2-directed maintenance may be preferable to indefinite target-plus-chemotherapy.
Abstract
Claudin 18.2 (CLDN18.2) has rapidly become a major target in solid-tumor oncology. Zolbetuximab, the first anti-CLDN18.2 antibody, was approved in 2024 for HER2-negative, CLDN18.2-high advanced gastric and gastro-esophageal junction adenocarcinoma, and more than one hundred CLDN18.2-directed trials are now under way across monoclonal antibodies, antibody-drug conjugates, bispecific antibodies and CAR-T cells. As these agents enter the clinic, resistance has become the central challenge. This review synthesizes the resistance mechanisms emerging from this experience and organizes them into six biological dimensions, separating those distinctive to CLDN18.2 from those shared across therapeutic platforms, and pairs each with mechanism-matched countermeasures weighted by level of evidence. From this synthesis we advance a central argument about treatment sequencing: because CLDN18.2 expression declines progressively under therapeutic pressure, continuous target-plus-chemotherapy acts on an eroding antigen substrate. For patients with high, homogeneous baseline expression, an early intensive induction followed by CLDN18.2-directed maintenance may therefore be preferable to indefinite target-plus-chemotherapy. We further consider the tissue-context-dependent biology of CLDN18.2 relevant to patient selection, and outline the prospective, biomarker-embedded trials needed to test these proposals.
This article systematically elaborates the molecular structure, expression regulatory mechanisms and clinicopathological value of CLDN18.2 based on the data of 58 global clinical trials, and analyzes the current status, existing problems in testing standardization and drug development.
Current evidence through July 2026 is summarized, plausible mechanisms of resistance and biomarker evolution are examined, and a cautious, modality-specific framework for future clinical development is proposed.
T. Sagawa, H. Nagashima, K. Fujikawa· Journal of Gastrointestinal...· 0 citations
ABBV-CLS-484 is tolerable, with preliminary evidence of clinical activity in dose escalation, and additional strategies that combine ABBV-CLS-484 with VEGF TKIs, CAR-T therapy, and T cell engagers are being tested in preclinical models.
H. Hammers, E. Calvo, B. Carneiro et al.· The Oncologist· 0 citations
Colorectal cancer (CRC) remains a leading cause of cancer‐related mortality worldwide. Approximately 15% of localized and 5% of metastatic cases exhibit mismatch repair deficiency (dMMR) or high microsatellite instability (MSI‐H). While immune checkpoint inhibitors (ICIs) have revolutionized the first‐line treatment fo...
Ke Zhou, Ping Lu, Hong-Li Xu et al.· Journal of Immunological Res...· 0 citations
Abstract Background Renal cell carcinoma (RCC) is characterized by an immunogenic tumor microenvironment and frequent activation of angiogenic pathways. Therefore, combining immune checkpoint blockade with VEGF pathway inhibition is a rational therapeutic approach. PF‑08634404 is an investigational anti–PD‑1 and anti‑V...
T. Choueiri, S. Pal, T. Powles et al.· The Oncologist· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.